In advanced hip OA, Depo-Medrone demonstrated significant relief of acute pain1
Mean change in Numerical Rating Scale (NRS)* scores over 8 weeks1
- Depo-Medrone demonstrated significant improvement from baseline in WOMAC pain and function global scores1
- Effect sizes† indicated the benefit of Depo-Medrone was substantial in improving NRS pain scores and WOMAC pain and function scores from baseline1
- Depo-Medrone was well tolerated during the treatment period1
In analyses of clinical studies by AHRQ‡
Patients with early RA receiving low-dose corticosteroids plus DMARD therapy versus patients receiving DMARD therapy alone showed:
- Significantly less radiographic progression (over 1-2 years)2
- Better remission (DAS <2.6) scores2
- Greater improvements in functional capacity and less work disability2
In a head-to-head trial vs triamcinolone hexacetonide (THA)
Depo-Medrone: significant improvement of inflammation-related OA knee pain3
Significant improvement in Visual Analogue Scale (VAS) compared with THA3
- Depo-Medrone was similar to THA in delivering significant improvement in pain (VAS) and disability LEQ at week 33
- Only Depo-MedroneL maintained significant improvement in both measures at week 8 (P<.05)3
- In additional analyses, Depo-Medrone also improved postoperative recovery in knee OA and significantly reduced the incidence and severity of cartilage erosions4,
Depo-Medrone demonstrated rapid and sustained relief of shoulder pain due to subacromial bursitis5
- Depo-Medrone delivered similar mean pain relief (61%) to triamcinolone (TMC) at 2 weeks5
Change in VAS after injection
- More patients in the Depo-Medrone group sustained pain relief (VAS) of 50% or more 2 weeks post injection (P=.02)5
- Depo-Medrone also improved ROM by a mean of 33%, comparable to TMC5
- Patients treated with Depo-Medrone experienced more rapid pain relief than patients receiving TMC5
*NRS is calculated on a pain scale of 0-101.
† Effect size was calculated as the mean change from baseline divided by the baseline SD1.
‡ Agency for Healthcare Research and Quality (Department of Health and Human Services).
β Suggested dosage in Depo-Medrone SPC for a large joint (knee, ankle, shoulder): 20 – 80 mg.
- Atchia I, Kane D, Reed MR, et al. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Ann Rheum Dis. 2011;70:110-116.
- Donahue KE, Jonas DE, Hansen RA, et al. Drug therapy for rheumatoid arthritis in adults: an update. Agency Health Res Qual. 2012. ARQ Publication No. 12 EHC025-EF.
- Pyne D, Ioannou Y, Mootoo R, Bhanji A. Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate. Clin Rheumatol. 2004;23:116-120.
- Koyonos L, Yanke AB, McNickle AG, et al. A randomized, prospective, double-blind study to investigate the effectiveness of adding Depo-Medrol to a local anesthetic injection in postmeniscectomy patients with osteoarthritis of the knee. Am J Sports Med. 2009;37(6):1077-1082.
- Chávez-López MA, Navarro-Soltero LA, Rosas-Cabral AR, et al. Methylprednisolone versus triamcinolone in painful shoulder using ultrasound-guided injection. Mod Rheum. 2009;19:147-150.